Advertisement

Molecular Medicine

, Volume 18, Issue 6, pp 971–981 | Cite as

Neuroprotective Effects of Toll-Like Receptor 4 Antagonism in Spinal Cord Cultures and in a Mouse Model of Motor Neuron Degeneration

  • Massimiliano De Paola
  • Alessandro Mariani
  • Paolo Bigini
  • Marco Peviani
  • Giovanni Ferrara
  • Monica Molteni
  • Sabrina Gemma
  • Pietro Veglianese
  • Valeria Castellaneta
  • Valentina Boldrin
  • Carlo Rossetti
  • Chiara Chiabrando
  • Gianluigi Forloni
  • Tiziana Mennini
  • Roberto Fanelli
Research Article

Abstract

Sustained inflammatory reactions are common pathological events associated with neuron loss in neurodegenerative diseases. Reported evidence suggests that Toll-like receptor 4 (TLR4) is a key player of neuroinflammation in several neurodegenerative diseases. However, the mechanisms by which TLR4 mediates neurotoxic signals remain poorly understood. We investigated the role of TLR4 in in vitro and in vivosettings of motor neuron degeneration. Using primary cultures from mouse spinal cords, we characterized both the proinflammatory and neurotoxic effects of TLR4 activation with lipopolysaccharide (activation of microglial cells, release of proinflammatory cytokines and motor neuron death) and the protective effects of a cyanobacteriaderived TLR4 antagonist (VB3323). With the use of TLR4-deficient cells, a critical role of the microglial component with functionally active TLR4 emerged in this setting. The in vivo experiments were carried out in a mouse model of spontaneous motor neuron degeneration, the wobbler mouse, where we preliminarily confirmed a protective effect of TLR4 antagonism. Compared with vehicle- and riluzole-treated mice, those chronically treated with VB3323 showed a decrease in microglial activation and morphological alterations of spinal cord neurons and a better performance in the paw abnormality and grip-strength tests. Taken together, our data add new understanding of the role of TLR4 in mediating neurotoxicity in the spinal cord and suggest that TLR4 antagonists could be considered in future studies as candidate protective agents for motor neurons in degenerative diseases.

Notes

Acknowledgments

This work was partially supported by the Lombardy Region Found for the Promotion of Institutional Agreements (NEPENTE [Network lombardo di eccellenza per lo sviluppo di farmaci di origine naturale diretti alla modulazione del microambiente tissutale per la prevenzione e terapia dei tumori e delle malattie neurodegenerative] project ID 14501). A fellowship to A Mariani was funded by the Cariplo Foundation (grant 2009–2426) (Milan, Italy). The authors acknowledge Alessandro Soave for artwork and Judy Baggott for the English revision.

Supplementary material

10020_2012_1806971_MOESM1_ESM.pdf (1.4 mb)
Neuroprotective Effects of Toll-Like Receptor 4 Antagonism in Spinal Cord Cultures and in a Mouse Model of Motor Neuron Degeneration

References

  1. 1.
    Marsh BJ, Stevens SL, Hunter B, Stenzel-Poore MP. (2009) Inflammation and the emerging role of the toll-like receptor system in acute brain ischemia. Stroke. 40:S34–7.CrossRefGoogle Scholar
  2. 2.
    Tahara K, et al. (2006) Role of toll-like receptor signalling in Abeta uptake and clearance. Brain. 129:3006–19.CrossRefGoogle Scholar
  3. 3.
    Chakravarty S, Herkenham M. (2005) Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J. Neurosci. 25:1788–96.CrossRefGoogle Scholar
  4. 4.
    Tang SC, et al. (2008) Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol. 213:114–21.CrossRefGoogle Scholar
  5. 5.
    Abate W, Alghaithy AA, Parton J, Jones KP, Jackson SK. (2009) Surfactant lipids regulate LPS-induced interleukin-8 production in A549 lung epithelial cells by inhibiting translocation of TLR4 into lipid raft domains. J. Lipid Res. 51:334–44.CrossRefGoogle Scholar
  6. 6.
    Hoshino K, et al. (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:3749–52.PubMedGoogle Scholar
  7. 7.
    Takeda K, Akira S. (2001) Roles of Toll-like receptors in innate immune responses. Genes Cells. 6:733–42.CrossRefGoogle Scholar
  8. 8.
    Flo TH, et al. (2000) Involvement of CD14 and beta2-integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers. Infect. Immun. 68:6770–6.CrossRefGoogle Scholar
  9. 9.
    Tobias PS, Tapping RI, Gegner JA. (1999) Endotoxin interactions with lipopolysaccharideresponsive cells. Clin. Infect. Dis. 28:476–81.CrossRefGoogle Scholar
  10. 10.
    Muller-Loennies S, et al. (1998) What we know and don’t know about the chemical and physical structure of lipopolysaccharide in relation to biological activity. Prog. Clin. Biol. Res. 397:51–72.PubMedGoogle Scholar
  11. 11.
    Lien E, et al. (2000) Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J. Clin. Invest. 105:497–504.CrossRefGoogle Scholar
  12. 12.
    Shimazu R, et al. (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189:1777–82.CrossRefGoogle Scholar
  13. 13.
    Walter S, et al. (2007) Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease. Cell Physiol. Biochem. 20:947–56.CrossRefGoogle Scholar
  14. 14.
    Panaro MA, et al. (2008) Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson’s-like disease. Immunopharmacol. Immunotoxicol. 30:729–40.CrossRefGoogle Scholar
  15. 15.
    Bsibsi M, Ravid R, Gveric D, van Noort JM. (2002) Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 61:1013–21.CrossRefGoogle Scholar
  16. 16.
    Letiembre M, et al. (2009) Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol. Aging. 30:759–68.CrossRefGoogle Scholar
  17. 17.
    Casula M, et al. (2011) Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience. 179:233–43.CrossRefGoogle Scholar
  18. 18.
    Schmitt-John T, et al. (2005) Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat. Genet. 37:1213–5.CrossRefGoogle Scholar
  19. 19.
    Liewen H, et al. (2005) Characterization of the human GARP (Golgi associated retrograde protein) complex. Exp. Cell Res. 306:24–34.CrossRefGoogle Scholar
  20. 20.
    Beghi E, Mennini T. (2004) Basic and clinical research on amyotrophic lateral sclerosis and other motor neuron disorders in Italy: recent findings and achievements from a network of laboratories. Neurol. Sci. 25 (Suppl. 2):S41–60.CrossRefGoogle Scholar
  21. 21.
    Bigini P, Bastone A, Mennini T. (2001) Glutamate transporters in the spinal cord of the wobbler mouse. Neuroreport. 12:1815–20.CrossRefGoogle Scholar
  22. 22.
    Boillee S, Viala L, Peschanski M, Dreyfus PA. (2001) Differential microglial response to progressive neurodegeneration in the murine mutant Wobbler. Glia. 33:277–87.CrossRefGoogle Scholar
  23. 23.
    Rathke-Hartlieb S, Schmidt VC, Jockusch H, Schmitt-John T, Bartsch JW. (1999) Spatiotemporal progression of neurodegeneration and glia activation in the wobbler neuropathy of the mouse. Neuroreport. 10:3411–6.CrossRefGoogle Scholar
  24. 24.
    Schlomann U, Rathke-Hartlieb S, Yamamoto S, Jockusch H, Bartsch JW. (2000) Tumor necrosis factor alpha induces a metalloproteasedisintegrin, ADAM8 (CD 156): implications for neuron-glia interactions during neurodegeneration. J. Neurosci. 20:7964–71.CrossRefGoogle Scholar
  25. 25.
    D.L. no. 116, G.U. suppl. 40, 18 February 1992.Google Scholar
  26. 26.
    Circolare no. 8, G.U., 14 Luglio 1994.Google Scholar
  27. 27.
    EEC Council Directive 86/609, OJ L 358, 1, Dec. 12, 1987.Google Scholar
  28. 28.
    Institute of Laboratory Animal Resources; Commission on Life Sciences; National Research Council. (1996) Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academy Press. [cited 2012 Jul 30]. Available from: https://doi.org/www.nap.edu/openbook.php?record_id=5140Google Scholar
  29. 29.
    De Paola M, Diana V, Bigini P, Mennini T. (2008) Morphological features and responses to AMPA receptor-mediated excitotoxicity of mouse motor neurons: comparison in purified, mixed anterior horn or motor neuron/glia cocultures. J. Neurosci. Methods. 170:85–95.CrossRefGoogle Scholar
  30. 30.
    Hamby ME, Uliasz TF, Hewett SJ, Hewett JA. (2006) Characterization of an improved procedure for the removal of microglia from confluent monolayers of primary astrocytes. J. Neurosci. Methods. 150:128–37.CrossRefGoogle Scholar
  31. 31.
    Gingras M, Gagnon V, Minotti S, Durham HD, Berthod F. (2007) Optimized protocols for isolation of primary motor neurons, astrocytes and microglia from embryonic mouse spinal cord. J. Neurosci. Methods. 163:111–18.CrossRefGoogle Scholar
  32. 32.
    Macagno A, et al. (2006) A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. J. Exp. Med. 203:1481–92.CrossRefGoogle Scholar
  33. 33.
    Jemmett K, et al. (2008) A cyanobacterial lipopolysaccharide antagonist inhibits cytokine production induced by Neisseria meningitidis in a human whole-blood model of septicemia. Infect. Immun. 76:3156–63.CrossRefGoogle Scholar
  34. 34.
    Blesch A. (2004) Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer. Methods. 33:164–72.CrossRefGoogle Scholar
  35. 35.
    Fumagalli E, Bigini P, Barbera S, De Paola M, Mennini T. (2006) Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Exp. Neurol. 198:114–28.CrossRefGoogle Scholar
  36. 36.
    Bigini P, Mennini T. (2004) Immunohistochemical localization of TNFalpha and its receptors in the rodent central nervous system. Methods Mol. Med. 98:73–80.PubMedGoogle Scholar
  37. 37.
    Bigini P, et al. (2007) Lack of caspase-dependent apoptosis in spinal motor neurons of the wobbler mouse. Neurosci. Lett. 426:106–10.CrossRefGoogle Scholar
  38. 38.
    Bigini P, et al. (2008) Recombinant human TNF-binding protein-1 (rhTBP-1) treatment delays both symptoms progression and motor neuron loss in the wobbler mouse. Neurobiol. Dis. 29:465–76.CrossRefGoogle Scholar
  39. 39.
    Lehnardt S, et al. (2002) The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J. Neurosci. 22:2478–86.CrossRefGoogle Scholar
  40. 40.
    Wood PL. (1995) Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. Neurol. Res. 17:242–8.CrossRefGoogle Scholar
  41. 41.
    Madrigal JL, Feinstein DL, Dello Russo C. (2005) Norepinephrine protects cortical neurons against microglial-induced cell death. J. Neurosci. Res. 81:390–6.CrossRefGoogle Scholar
  42. 42.
    Heneka MT, et al. (2002) Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer’s disease. J. Neurosci. 22:2434–42.CrossRefGoogle Scholar
  43. 43.
    Banks WA, Erickson MA. (2010) The blood-brain barrier and immune function and dysfunction. Neurobiol. Dis. 37:26–32.CrossRefGoogle Scholar
  44. 44.
    Maroso M, et al. (2010) Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med. 16:413–9.CrossRefGoogle Scholar
  45. 45.
    Christianson CA, et al. (2011) Spinal TLR4 mediates the transition to a persistent mechanical hypersensitivity after the resolution of inflammation in serum-transferred arthritis. Pain. 152:2881–91.CrossRefGoogle Scholar
  46. 46.
    Mazarati A, Maroso M, Iori V, Vezzani A, Carli M. (2011) High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and receptor for advanced glycation end products. Exp. Neurol. 232:143–8.CrossRefGoogle Scholar
  47. 47.
    Netea MG, van Deuren M, Kullberg BJ, Cavaillon JM, Van der Meer JW. (2002) Does the shape of lipid A determine the interaction of LPS with Toll-like receptors? Trends Immunol. 23:135–9.CrossRefGoogle Scholar
  48. 48.
    Alexianu ME, Kozovska M, Appel SH. (2001) Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 57:1282–9.CrossRefGoogle Scholar
  49. 49.
    Tortarolo M, et al. (2003) Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol. Cell. Neurosci. 23:180–92.CrossRefGoogle Scholar
  50. 50.
    Yoshihara T, et al. (2002) Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 80:158–67.CrossRefGoogle Scholar
  51. 51.
    Bensimon G, Lacomblez L, Meininger V. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis: ALS/Riluzole Study Group. N. Engl. J. Med. 330:585–91.CrossRefGoogle Scholar
  52. 52.
    Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis: Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347:1425–31.CrossRefGoogle Scholar
  53. 53.
    Miller RG, Mitchell JD, Lyon M, Moore DH. (2003) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph. Lateral Scler. Other Motor Neuron Disord. 4:191–206.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Massimiliano De Paola
    • 1
  • Alessandro Mariani
    • 1
  • Paolo Bigini
    • 2
  • Marco Peviani
    • 3
  • Giovanni Ferrara
    • 3
  • Monica Molteni
    • 4
  • Sabrina Gemma
    • 4
  • Pietro Veglianese
    • 3
  • Valeria Castellaneta
    • 2
  • Valentina Boldrin
    • 3
  • Carlo Rossetti
    • 5
  • Chiara Chiabrando
    • 1
  • Gianluigi Forloni
    • 3
  • Tiziana Mennini
    • 2
  • Roberto Fanelli
    • 1
  1. 1.Department of Environmental Health SciencesMario Negri Institute for Pharmacological ResearchMilanItaly
  2. 2.Department of Biochemistry and Molecular PharmacologyMario Negri Institute for Pharmacological ResearchMilanItaly
  3. 3.Department of NeuroscienceMario Negri Institute for Pharmacological ResearchMilanItaly
  4. 4.Bluegreen BiotechMario Negri Institute for Pharmacological ResearchMilanItaly
  5. 5.Department of Biotechnology and Molecular SciencesUniversity of InsubriaVareseItaly

Personalised recommendations